Article
Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.
Neuro-oncology - 19 Oct 2017
Sepúlveda-Sánchez Juan Manuel, Vaz María Ángeles, Balañá Carmen, Gil-Gil Miguel, Reynés Gaspar, Gallego Óscar, Martínez-García María, Vicente Elena, Quindós María, Luque Raquel, Ramos Ana, Ruano Yolanda, Pérez-Segura Pedro, Benavides Manuel, Sánchez-Gómez Pilar, Hernández-Laín Aurelio
Abstract excerpt
BACKGROUND: We conducted a multicenter, 2-stage, open-label, phase II trial to assess the efficacy and safety of dacomitinib in adult patients with recurrent glioblastoma (GB) and epidermal growth factor receptor gene (EGFR) amplification with or without variant III (EGFRvIII) deletion. METHODS: Patients with first recurrence were enrolled in 2 cohorts. Cohort A included patients with EGFR gene amplification...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.